<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PIOGLITAZONE HYDROCHLORIDE</span><br/>(pi-o-glit'a-zone)<br/><span class="topboxtradename">Actos<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">antidiabetic</span>; <span class="classification">thiazolidinedione</span><br/><b>Prototype: </b>Rosiglitazone Maleate<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>15 mg, 30 mg, 45 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Results in insulin sensitivity by affecting insulin receptors. Decreases hepatic glucose output and increases insulin-dependent
         muscle glucose uptake in skeletal muscle and adipose tissue.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Improves glycemic control in noninsulin dependent diabetic (type 2) patients by enhancing insulin sensitivity of cells without
         stimulating pancreatic insulin secretion. Indicated by improved blood glucose levels and decreased HbA<sub>1c</sub>.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct to diet in the treatment of type 2 diabetes mellitus.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to pioglitazone, troglitazone, rosiglitazone, englitazone; type 1 diabetes, or treatment of DKA; active liver
         disease or ALT levels &gt;2.5 times normal limit; pregnancy (category C), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Liver dysfunction; cardiovascular disease [New York Heart Association (NYHA)] Class III and Class IV (e.g., CHF); hypertension,
         edema; renal impairment; older adults. Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Type 2 Diabetes Mellitus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1530 mg once daily (max: 45 mg q.d.)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give without regard to food.</li>
<li>Do not initiate therapy if baseline serum ALT &gt;2.5 times normal.</li>
<li>Store at 15°30° C (59°86° F) in tightly closed container; protect from humidity and moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Headache, myalgia, edema. <span class="typehead">CV:</span> Edema, fluid retention, exacerbation of heart failure. <span class="typehead">GI:</span> Tooth disorder. <span class="typehead">Respiratory:</span>
<span class="speceff-common">Upper respiratory tract infection,</span> sinusitis, pharyngitis. <span class="typehead">Metabolic:</span> Hypoglycemia, mild anemia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Pioglitazone</b> may decrease serum levels of <span class="classification">oral contraceptives</span>; <b>ketoconazole</b> may increase serum levels of <b>pioglitazone.</b>
<span class="typehead">Herbal:</span>
<b>Garlic,</b>
<b>ginseng</b> may potentiate hypoglycemic effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed. <span class="typehead">Peak:</span> 2 h; steady state concentrations within 7 d. <span class="typehead">Duration:</span> 24 h. <span class="typehead">Distribution:</span> &gt;99% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver to active metabolites. <span class="typehead">Elimination:</span> Primarily excreted in bile and feces. <span class="typehead">Half-Life:</span> 1624 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S hypoglycemia (possible when insulin/sulfonylureas are coadministered).</li>
<li>Monitor closely for S&amp;S of CHF or exacerbation of symptoms with preexisting CHF.</li>
<li>Lab tests: Baseline serum ALT, then q2mo for first y, then periodically (more often if elevated); periodic HbA<sub>1c</sub>, Hgb and Hct, and lipid profile.
         </li>
<li>Discontinue drug if ALT &gt;3 times ULN or patient has jaundice.</li>
<li>Monitor weight and notify physician of development of edema.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that resumed ovulation is possible in nonovulating premenopausal women.</li>
<li>Use or add barrier contraceptive if using hormonal contraception.</li>
<li>Report immediately to physician: Unexplained anorexia, nausea, vomiting, abdominal pain, fatigue, dark urine; or S&amp;S of fluid
            retention such as weight gain, edema, or activity intolerance.
         </li>
<li>Combination therapy: May need adjustment of other antidiabetic drugs to avoid hypoglycemia.</li>
<li>Learn of and adhere strictly to guideliness for liver function tests. Be sure to have blood tests for liver function every
            2 mo for first y; then periodically.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>